Centessa Pharmaceuticals plc

Centessa Pharmaceuticals Misses on Revenue, Stock Down 2.53%

This earnings report indicates that while Centessa Pharmaceuticals exceeded EPS expectations, the lack of revenue details and guidance may raise concerns among investors. The stock reacted negatively, dropping 2.53%, likely due to uncertainty about future performance and the absence of concrete financial metrics.